iTeos Therapeutics launched to develop immunomodulators
New Company to Focus on Developing Novel Immunotherapy Compounds for Cancer Treatment
07-May-2012
- Belgium
iTeos’ initial goals are to reach a proof of concept in humans by completing a Phase I/IIa study for the first compound program and to submit an Investigational New Drug application for a second candidate in four years.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.